ClinicalTrials.gg

Program

Azacitidine

Also written as “azacitidine”, “Azacitidine (AZA)” and “Eganelisib in combination with azacitidine”.

Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Hematologic Neoplasms · Lymphoma, T-Cell, led by 9 companies.

Furthest: phase 4, since Sep 13, 201027 company-led studies, 3 open or runningNext primary completion: Jul 13, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb161 open or runningphase 4since Sep 13, 2010Oct 31, 2003none ahead
Takeda30 open or runningphase 3since Aug 30, 2017May 28, 2009none ahead
Hikma Pharmaceuticals21 open or runningphase 1since Mar 11, 2024Mar 11, 2024none ahead
bioniche-pharma-usa-llc10 open or runningphase 1since Jun 25, 2010Jun 25, 2010none ahead
Johnson & Johnson10 open or runningphase 2since Feb 7, 2020Feb 7, 2020none ahead
Merck10 open or runningphase 2since Nov 24, 2014Nov 24, 2014none ahead
nanexa-ab10 open or runningphase 1since May 11, 2021May 11, 2021none ahead
Nob Hill Therapeutics11 open or runningphase 2since Sep 10, 2026Sep 10, 2026Jul 13, 2029phase 2 · NCT07864584
Sarah Cannon Research Institute10 open or runningphase 2since Oct 4, 2006Oct 4, 2006none ahead

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd, Hoffmann-La Roche, roche-genentech, takeda-development-center-americas-inc and argenx.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Oct 31, 2003.

  1. May 14, 2012Phase 2 study in Myelodysplastic SyndromesBristol-Myers Squibb · NCT01599325 · 72 enrolled · China
  2. Nov 24, 2014Merck's first study: phase 2 study in Leukemia, Myeloid, AcuteNew to MerckMerck · NCT02303782
  3. Apr 14, 2015Phase 2 study in Myelodysplastic SyndromesBristol-Myers Squibb · NCT02447666 · 28 enrolled · Austria, Belgium, Czechia and more
  4. May 19, 2015Phase 2 study in Leukemia, Myeloid, AcuteBristol-Myers Squibb · NCT02450877 · 7 enrolled · Denmark, Germany, Netherlands
  5. Feb 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteBristol-Myers Squibb · NCT02677922 · 130 enrolled · United States, Australia, Belgium and more
  6. May 20, 2016Phase 1 study in Leukemia, Myeloid, AcuteTakeda · NCT02782468 · 23 enrolled · Japan, Korea, Republic of, Taiwan
  7. Aug 30, 2017Phase 3 study in Myelodysplastic SyndromesTakeda · NCT03268954 · 454 enrolled · United States, Australia, Belgium and more
  8. Oct 9, 2018Phase 3 study in Lymphoma, T-CellBristol-Myers Squibb · NCT03703375 · 93 enrolled · Japan
  9. Feb 7, 2020Johnson & Johnson's first study: phase 2 study in Myelodysplastic SyndromesNew to Johnson & JohnsonJohnson & Johnson · NCT04264806 · Australia, Brazil, France and more
  10. Feb 2, 2021Phase 1 study in Leukemia, MyeloidBristol-Myers Squibb · NCT04748848 · 1 enrolled · United States, Belgium, France and more
  11. May 11, 2021nanexa-ab's first study: phase 1 study in Myelodysplastic SyndromesNew to nanexa-abnanexa-ab · NCT05048498 · 2 enrolled · Sweden
  12. Mar 11, 2024Hikma Pharmaceuticals's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT06326697 · 32 enrolled · Saudi Arabia
  13. Aug 22, 2024No phase study in Leukemia, Myeloid, AcuteHikma Pharmaceuticals · NCT06572982 · 20 enrolled · United Arab Emirates
  14. Sep 10, 2026Nob Hill Therapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Nob Hill TherapeuticsNob Hill Therapeutics · NCT07864584 · 100 planned · United States

Ahead

  1. Jul 13, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNob Hill Therapeutics · NCT07864584

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07864584Carcinoma, Non-Small-Cell Lung · United States2Not yet recruitingNob Hill TherapeuticsJul 13, 2029100
NCT06572982Leukemia, Myeloid, Acute · United Arab Emirates–Active, not recruitingHikma PharmaceuticalsMay 202620
NCT06326697Leukemia, Myeloid, Acute · Saudi Arabia1CompletedHikma PharmaceuticalsAug 17, 202532
NCT05048498Myelodysplastic Syndromes · Sweden1Completednanexa-abFeb 10, 20222
NCT04748848Leukemia, Myeloid · United States, Belgium, France and more1TerminatedBristol-Myers SquibbMar 9, 20221
NCT04264806Myelodysplastic Syndromes · Australia, Brazil, France and more2WithdrawnJohnson & JohnsonApr 19, 20220
NCT03703375Lymphoma, T-Cell · Japan3CompletedBristol-Myers SquibbFeb 10, 202193
NCT03268954Myelodysplastic Syndromes · United States, Australia, Belgium and more3CompletedTakedaMay 28, 2021454
NCT02782468Leukemia, Myeloid, Acute · Japan, Korea, Republic of, Taiwan1CompletedTakedaJan 25, 202223
NCT02677922Leukemia, Myeloid, Acute · United States, Australia, Belgium and more2Active, not recruitingBristol-Myers SquibbAug 2, 2018130
NCT02450877Leukemia, Myeloid, Acute · Denmark, Germany, Netherlands2CompletedBristol-Myers SquibbOct 10, 20187
NCT02447666Myelodysplastic Syndromes · Austria, Belgium, Czechia and more2CompletedBristol-Myers SquibbFeb 28, 201828
NCT02303782Leukemia, Myeloid, Acute2WithdrawnMerckMar 20160
NCT01599325Myelodysplastic Syndromes · China2CompletedBristol-Myers SquibbJan 29, 201572
NCT01358734Leukemia, Myeloid, Acute · United States, Canada2CompletedBristol-Myers SquibbMay 19, 201588
NCT01201811Myelodysplastic Syndromes · Taiwan4CompletedBristol-Myers SquibbMay 1, 201344
NCT01186939Myelodysplastic Syndromes · Australia, Bulgaria, France and more3CompletedBristol-Myers SquibbSep 1, 200940
NCT01152346Myelodysplastic Syndromes · United States, France1Completedbioniche-pharma-usa-llcDec 201219
NCT01074047Leukemia, Myeloid, Acute · United States, Australia, Austria and more3CompletedBristol-Myers SquibbJan 22, 2014488
NCT00911066Leukemia, Myeloid, Acute · United States1CompletedTakedaAug 201372
NCT00761722Leukemia, Myeloid, Acute · United States1CompletedBristol-Myers SquibbApr 6, 201631
NCT00666497Leukemia, Myeloid, Acute · United States, Canada, United Kingdom2TerminatedBristol-Myers SquibbApr 20096
NCT00652626Multiple Myeloma · United States1CompletedBristol-Myers SquibbJul 1, 201231
NCT00528983Myelodysplastic Syndromes · United States1CompletedBristol-Myers SquibbJul 31, 2013133
NCT00384839Prostatic Neoplasms · United States2CompletedSarah Cannon Research InstituteNov 200936
NCT00102687Myelodysplastic Syndromes · United States2CompletedBristol-Myers SquibbAug 1, 2008151
NCT00071799Myelodysplastic Syndromes · United States, Australia, Bulgaria and more3CompletedBristol-Myers SquibbJul 1, 2007358

How it is read

Names in the registry

  • “Azacitidine”, 36 entries
  • “azacitidine”, 8 entries
  • “Azacitidine (AZA)”, 2 entries
  • “Eganelisib in combination with azacitidine”, 1 entry
  • “NHT102”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.